Volume 55, Issue 6, Pages (June 1999)

Slides:



Advertisements
Similar presentations
Lymphatic vessels develop during tubulointerstitial fibrosis
Advertisements

Volume 64, Issue 6, Pages (December 2003)
Volume 59, Issue 3, Pages (March 2001)
Volume 65, Issue 2, Pages (February 2004)
Volume 54, Issue 5, Pages (November 1998)
Osteopontin expression in human crescentic glomerulonephritis
Volume 54, Issue 6, Pages (January 1998)
Volume 56, Issue 4, Pages (October 1999)
Volume 54, Issue 1, Pages (July 1998)
Volume 54, Issue 3, Pages (September 1998)
Volume 61, Issue 2, Pages (February 2002)
Volume 58, Issue 3, Pages (September 2000)
Volume 60, Issue 6, Pages (December 2001)
Volume 64, Issue 1, Pages (July 2003)
Volume 60, Issue 2, Pages (August 2001)
Volume 54, Issue 6, Pages (January 1998)
Volume 70, Issue 7, Pages (October 2006)
Volume 61, Issue 5, Pages (May 2002)
Volume 68, Issue 5, Pages (November 2005)
Volume 55, Issue 5, Pages (May 1999)
Volume 62, Issue 6, Pages (December 2002)
Volume 56, Issue 6, Pages (December 1999)
Volume 54, Issue 3, Pages (September 1998)
Volume 58, Issue 2, Pages (August 2000)
Volume 63, Issue 4, Pages (April 2003)
Volume 59, Issue 1, Pages (January 2001)
Volume 60, Issue 3, Pages (September 2001)
Volume 59, Issue 4, Pages (April 2001)
Volume 55, Issue 4, Pages (April 1999)
Volume 56, Issue 3, Pages (September 1999)
Yang Wang, Yi Ping Wang, Yuet-Ching Tay, David C.H. Harris 
The renal lesions that develop in neonatal mice during angiotensin inhibition mimic obstructive nephropathy  Yoichi Miyazaki, Shinya Tsuchida, Agnes Fogo,
Volume 54, Issue 5, Pages (November 1998)
Volume 53, Issue 5, Pages (May 1998)
Volume 57, Issue 2, Pages (October 2000)
Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy  Shinya Mizuno, Kunio Matsumoto, Toshikazu Nakamura 
Volume 71, Issue 1, Pages (January 2007)
Lupus Nephritis: Proliferative Forms (WHO III, IV)
Volume 60, Issue 6, Pages (December 2001)
Volume 53, Issue 5, Pages (May 1998)
Volume 58, Issue 1, Pages (July 2000)
Volume 62, Issue 2, Pages (August 2002)
Volume 61, Issue 6, Pages (June 2002)
Lymphatic vessels develop during tubulointerstitial fibrosis
Volume 55, Issue 2, Pages (February 1999)
Volume 60, Issue 6, Pages (December 2001)
Volume 57, Issue 3, Pages (March 2000)
Volume 63, Issue 6, Pages (June 2003)
Role of CD8+ cells in the progression of murine adriamycin nephropathy
Volume 53, Issue 5, Pages (May 1998)
Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin- induced acute kidney injury  K. Negishi, E. Noiri, R. Maeda, D.
Volume 63, Issue 4, Pages (April 2003)
Volume 61, Issue 6, Pages (June 2002)
Wei-Zhong Ying, Pei-Xuan Wang, Paul W. Sanders  Kidney International 
Volume 65, Issue 2, Pages (February 2004)
Expression of connective tissue growth factor in human renal fibrosis
Volume 63, Issue 2, Pages (February 2003)
C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis  Gopala K. Rangan, Jeffrey W. Pippin, William.
B. Li, T. Morioka, M. Uchiyama, T. Oite  Kidney International 
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis  H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo 
Volume 57, Issue 6, Pages (June 2000)
Volume 68, Issue 2, Pages (August 2005)
Volume 64, Issue 3, Pages (September 2003)
Volume 58, Issue 4, Pages (October 2000)
Volume 59, Issue 5, Pages (May 2001)
Volume 56, Issue 6, Pages (December 1999)
Volume 58, Issue 3, Pages (September 2000)
Volume 61, Issue 6, Pages (June 2002)
Volume 65, Issue 1, Pages (January 2004)
Volume 56, Issue 4, Pages (October 1999)
Presentation transcript:

Volume 55, Issue 6, Pages 2310-2321 (June 1999) Heparin-binding epidermal growth factor-like growth factor is expressed in the adhesive lesions of experimental focal glomerular sclerosis  Kathy Paizis, Geoffrey Kirkland, Tiffany Khong, Marina Katerelos, Scott Fraser, John Kanellis, David A. Power  Kidney International  Volume 55, Issue 6, Pages 2310-2321 (June 1999) DOI: 10.1046/j.1523-1755.1999.00469.x Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 1 PAS staining of paraformaldehyde-fixed sections. (a) Passive Heymann nephritis at day 90. The kidney shows normal histology at this magnification (×62.5). (b) Chronic PAN at day 90. A glomerulus showing an extensive FGS lesion, together with an interstitial infiltrate and interstitial fibrosis is shown (×62.4). (c) Chronic PAN day 40, showing extensive tubular dilation, glomeruli with FGS, and interstitial fibrosis (×31.2). (d) Chronic PAN at day 40, showing extensive adhesions between the glomerulus and Bowman's capsule (×150). Kidney International 1999 55, 2310-2321DOI: (10.1046/j.1523-1755.1999.00469.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 2 Morphological characteristics of the chronic PAN model at days 40, 60, and 90 after induction. Symbols are: (□) normal; (▪) FGS < 25%; () FGS > 25%). (A) The percentage of glomeruli showing focal glomerulosclerosis involving less than 25% or more than 25% of the glomerular tuft circumference. (B) Semiquantitative assessment of the extent of tubulointerstitial fibrosis according to an arbitrary scale of 0 to 3. (C) Proliferating tubular cells expressed as the number per high power fields (HPF; ×100). All results are expressed as mean ± 1 sd. Kidney International 1999 55, 2310-2321DOI: (10.1046/j.1523-1755.1999.00469.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 3 Staining for BrdU-positive cells, ED-1, and α-smooth muscle actin. (a) Chronic PAN day 40, stained for BrdU incorporation. A number of positive cells are seen in a dilated tubule in the middle of the field (arrow; ×25). (b) Chronic PAN day 40, stained for BrdU incorporation. A number of positive cells are seen in Bowman's capsule (arrow) and in adjacent GECs of the capillary tuft (×125). (c) Passive Heymann nephritis day 90, stained for α-smooth muscle actin. The appearances are indistinguishable from normal (×50). (d) Chronic PAN day 90, stained for α-smooth muscle actin. Increased staining is seen in peritubular and periglomerular areas and within the glomerulus itself (×50). (e) Chronic PAN day 60, stained for macrophages with the mAb ED-1. Macrophages can be seen within one tubular cross-section (arrow; ×125). (f) A section of chronic PAN day 60 also stained with ED-1. Macrophage seen within the glomerulus (arrow; ×125). Kidney International 1999 55, 2310-2321DOI: (10.1046/j.1523-1755.1999.00469.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 4 Northern blot analysis of whole kidney RNA from rats with chronic puromycin aminonucleoside (PAN) and passive Heymann nephritis (PHN). (A) A representative Northern blot probed with heparin binding-epidermal growth factor (HB-EGF) cDNA followed by GAPDH. Abbreviations used are interpreted as follows: PHN 40, for example, refers to results from rats with chronic PHN at day 40 after induction. Similarly, PAN 40 refers to results from rats with chronic PAN 40days after induction, and so on. Nx is RNA from a nephrectomized control animal receiving saline. This control was performed to demonstrate that unilateral nephrectomy does not alter HB-EGF expression compared with kidneys from rats that have received no treatment. (B) The fold-induction of HB-EGF/GAPDH ratios, corrected within each of three separate experiments by using values obtained from a normal kidney as 1 (expressed as mean ± 1 sd). Asterisks denote significance values (P < 0.01 compared with PHN kidneys at the same time point). Kidney International 1999 55, 2310-2321DOI: (10.1046/j.1523-1755.1999.00469.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 5 In situ hybridization for HB-EGF in sections from passive Heymann nephritis and chronic PAN. All sections probed with antisense HB-EGF riboprobe. (a) A section from the chronic PAN control at day 40 showing faint tubular expression (×100). (b) Passive Heymann nephritis day 40, showing staining in the GEC's (arrow; ×100). (c) Chronic PAN day 90, showing intense staining in GEC's (thin arrow) and some tubules (thick arrow; ×100). (d) Chronic PAN day 40 showing strong expression in an FGS lesion (arrow; ×50). (e) Chronic PAN day 40, with a part of a glomerulus in the center of the section. The top of the glomerulus shows strong expression in cells at the center of an FGS lesion (arrow) and in GECs bordering the lesion (×200). (f) Chronic PAN day 40, with a part of a glomerulus in the center of the section. The top of the glomerulus shows expression in an early lesion of FGS (arrow; ×200). Kidney International 1999 55, 2310-2321DOI: (10.1046/j.1523-1755.1999.00469.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 6 Immunohistochemical staining of sections with anti-HB-EGF antibody. (a) A section from chronic PAN controls showing expression in tubules (×100). (b) Passive Heymann nephritis day 60, showing increased glomerular expression, predominantly in GECs, as well as an increase in tubular staining (×100). (c) Chronic PAN day 60, showing an increase in staining in an FGS lesion (×100). (d) Chronic PAN day 60, showing very prominent staining bordering an FGS lesion, following the line of Bowman's capsule (×120). (e) Higher power view of a section from chronic PAN day 90, with expression seen in a cell of Bowman's capsule (arrow) and in cells of the glomerular tuft (×200). (f) Chronic PAN day 90, showing staining of an adhesive lesion (arrow) and within the tuft (×200). Sections (g) and (h) are sequential. (g) Chronic PAN day 40 stained with anti–HB-EGF antibody (×62.5). (h) Sequential section stained for BrdU (×62.5). Dilated tubules with a number of BrdU-positive cells are indicated in both sections with a large star and a circled star. A tubule staining strongly for HB-EGF but with no BrdU-positive cells is marked with a small star. Kidney International 1999 55, 2310-2321DOI: (10.1046/j.1523-1755.1999.00469.x) Copyright © 1999 International Society of Nephrology Terms and Conditions